Jon S Odorico, MD

Professor

  • Section of Kidney and Pancreas Surgery
  • Division of Transplantation

jon@surgery.wisc.edu
(608) 263-0388

Clinical Science Center
600 Highland Avenue
Madison WI 53792

Education

  • MD, New York University, School of Medicine, New York, NY, 1987
  • Residency, General Surgery, Hospital of the University of Pennsylvania, Philadelphia, PA, 1987-1994
  • Postdoctoral Research Fellow, Harrison Department of Surgical Research, Hospital of the University of Pennsylvania, Philadelphia, PA, 1990-1992
  • Fellow, Transplant Surgery, University of Wisconsin Hospital and Clinics, Madison, WI, 1994-1996

Clinical Specialties

Dr. Odorico is certified by the American Board of Surgery. He specializes in pancreatic, islet cell, and multi-organ transplants.

Dr. Odorico provides a wide range of services including Kidney Transplant, Pancreas Transplant.

Research Interests

Dr. Odorico’s research focuses on stem cell biology and differentiation, developing novel stem cell-based strategies for treating diabetes, pancreas transplantation, and islet cell transplantation.
Dr. Odorico’s lab

Clinical Trials

Conversion from Immediate Release Tacrolimus to Envarsus XR® in Simultaneous Pancreas-Kidney Recipients: Assessment of functional, safety and quality of life outcomes (CIRTEN SPK)
Study sponsor: University of Wisconsin-Madison
Study funding provided by: Veloxis Pharmaceuticals
Jon S. Odorico, MD, Principal Investigator
10/18/2018 –present

Non Invasive Blood Test to Diagnose Acute Rejection After Pancreas and Kidney Transplantation: Pancreas and Renal Rejection Diagnosis Using Circulating Donor-Derived Cell-free DNA in Peripheral Blood (PANCDx)
Study funding provided by: CareDx
Jon S. Odorico, MD, Sub-Investigator
Subcontract Agreement Amendment under negotiation, we expect to start enrollment in the first quarter of 2020

Recent Publications

  • Letermovir conversion after valganciclovir treatment in cytomegalovirus high-risk abdominal solid organ transplant recipients may promote development of cytomegalovirus-specific cell mediated immunity.
    Jorgenson MR, Kleiboeker H, Garg N, Parajuli S, Mandelbrot DA, Odorico JS, Saddler CM, Smith JA
    Transpl Infect Dis 2021 Nov 20;
    [PubMed ID: 34799964]

  • Association of human leukocyte antigen mismatches between donor-recipient and donor-donor in pancreas after kidney transplant recipients.
    Parajuli S, Kaufman DB, Djamali A, Welch BM, Sollinger HW, Mandelbrot DA, Odorico JS
    Transpl Int 2021 Oct 13;
    [PubMed ID: 34644422]

  • Analysis of pancreatic extracellular matrix protein post-translational modifications via electrostatic repulsion-hydrophilic interaction chromatography coupled with mass spectrometry.
    Tabang DN, Cui Y, Tremmel DM, Ford M, Li Z, Sackett SD, Odorico JS, Li L
    Mol Omics 2021 Oct 11; 17(5): 652-664
    [PubMed ID: 34318855]

  • The addition of adjunctive letermovir to valganciclovir for refractory cytomegalovirus viremia in kidney transplant recipients.
    Jorgenson MR, Descourouez JL, Garg N, Parajuli S, Mandelbrot DA, Odorico JS, Saddler CM, Smith JA
    Transpl Infect Dis 2021 Aug; 23(4): e13693
    [PubMed ID: 34309158]

  • A pilot study of an intensified ganciclovir dosing strategy for treatment of cytomegalovirus disease in kidney and/or pancreas transplant recipients.
    Jorgenson MR, Descourouez JL, Leverson GE, Saddler CM, Smith JA, Garg N, Parajuli S, Mandelbrot DA, Odorico JS
    Clin Transplant 2021 Oct; 35(10): e14427
    [PubMed ID: 34263938]

All Publications on PubMed